Tags

Type your tag names separated by a space and hit enter

Efavirenz as a potential drug for the treatment of triple-negative breast cancers.
Clin Transl Oncol. 2020 Jun 21 [Online ahead of print]CT

Abstract

PURPOSE

In contrast to hormone receptor driven breast cancer, patients presenting with triple-negative breast cancer (TNBC) often have limited drug treatment options. Efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor targets abnormally overexpressed long interspersed nuclear element 1 (LINE-1) RT and has been shown to be a promising anticancer agent for treating prostate and pancreatic cancers. However, its effectiveness in treating patients with TNBC has not been comprehensively examined.

METHODS

In this study, the effect of Efavirenz on several TNBC cell lines was investigated by examining several cellular characteristics including viability, cell division and death, changes in cell morphology as well as the expression of LINE-1.

RESULTS

The results show that in a range of TNBC cell lines, Efavirenz causes cell death, retards cell proliferation and changes cell morphology to an epithelial-like phenotype. In addition, it is the first time that a whole-genome RNA sequence analysis has identified the fatty acid metabolism pathway as a key regulator in this Efavirenz-induced anticancer process.

CONCLUSION

In summary, we propose Efavirenz is a potential anti-TNBC drug and that its mode of action can be linked to the fatty acid metabolism pathway.

Authors+Show Affiliations

ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.Anatomical Pathology, ACT Pathology, Canberra Hospital and ANU Medical School, ANU College of Health and Medicine, The Australian National University, Canberra, ACT, Australia.ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia. marco.casarotto@anu.edu.au.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32566961

Citation

Chiou, P-T, et al. "Efavirenz as a Potential Drug for the Treatment of Triple-negative Breast Cancers." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020.
Chiou PT, Ohms S, Board PG, et al. Efavirenz as a potential drug for the treatment of triple-negative breast cancers. Clin Transl Oncol. 2020.
Chiou, P. T., Ohms, S., Board, P. G., Dahlstrom, J. E., Rangasamy, D., & Casarotto, M. G. (2020). Efavirenz as a potential drug for the treatment of triple-negative breast cancers. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. https://doi.org/10.1007/s12094-020-02424-5
Chiou PT, et al. Efavirenz as a Potential Drug for the Treatment of Triple-negative Breast Cancers. Clin Transl Oncol. 2020 Jun 21; PubMed PMID: 32566961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efavirenz as a potential drug for the treatment of triple-negative breast cancers. AU - Chiou,P-T, AU - Ohms,S, AU - Board,P G, AU - Dahlstrom,J E, AU - Rangasamy,D, AU - Casarotto,M G, Y1 - 2020/06/21/ PY - 2020/04/24/received PY - 2020/06/10/accepted PY - 2020/6/23/entrez KW - Efavirenz KW - Fatty acid metabolism KW - LINE-1 KW - Retrotransposon KW - Triple-negative breast cancer JF - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JO - Clin Transl Oncol N2 - PURPOSE: In contrast to hormone receptor driven breast cancer, patients presenting with triple-negative breast cancer (TNBC) often have limited drug treatment options. Efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor targets abnormally overexpressed long interspersed nuclear element 1 (LINE-1) RT and has been shown to be a promising anticancer agent for treating prostate and pancreatic cancers. However, its effectiveness in treating patients with TNBC has not been comprehensively examined. METHODS: In this study, the effect of Efavirenz on several TNBC cell lines was investigated by examining several cellular characteristics including viability, cell division and death, changes in cell morphology as well as the expression of LINE-1. RESULTS: The results show that in a range of TNBC cell lines, Efavirenz causes cell death, retards cell proliferation and changes cell morphology to an epithelial-like phenotype. In addition, it is the first time that a whole-genome RNA sequence analysis has identified the fatty acid metabolism pathway as a key regulator in this Efavirenz-induced anticancer process. CONCLUSION: In summary, we propose Efavirenz is a potential anti-TNBC drug and that its mode of action can be linked to the fatty acid metabolism pathway. SN - 1699-3055 UR - https://www.unboundmedicine.com/medline/citation/32566961/Efavirenz_as_a_potential_drug_for_the_treatment_of_triple-negative_breast_cancers L2 - https://dx.doi.org/10.1007/s12094-020-02424-5 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.